!– Request: support/webinars/standardizing-ngs-secondary-analysis-for-assay-development-and-routine-clinical-testing –> <!– Matched Rewrite Rule: support/webinars/(.+?)(?:/([0-9]+))?/?$ –> <!– Matched Rewrite Query: webinars=standardizing-ngs-secondary-analysis-for-assay-development-and-routine-clinical-testing&page= –> <!– Loaded Template: single-webinars.php –>
As next-generation sequencing (NGS) continues to become faster and cheaper, commensurate speeds and costs are required for NGS secondary analysis—the critical step that maps and aligns the sequence reads to a reference genome and identifies the genomic locations exhibiting variations. However, NGS secondary analysis involves sequences of steps, each performed by a software tool, that vary by application and introduce workflow complexities. To improve NGS assay development and routine clinical testing, clinical labs need automated and standardized secondary analysis pipelines.
In this webinar, we present a precision medicine platform for automating, managing and standardizing NGS secondary analysis for clinical research applications. QIAGEN Clinical Insight (QCI) Analyze provides sequencer-agnostic workflows for variant calling through pre-configured, comprehensive and expandable NGS secondary data analysis pipelines.
Julie Deschênes, MBA, PhD
Director Global Product Management for Hereditary Cancer, QIAGEN
Camilla Eybye Andersen, PhD
Senior Product Owner, QIAGEN